Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
7
×
national top stories
san francisco blog main
san francisco top stories
7
×
national
new york blog main
new york top stories
san diego blog main
san diego top stories
biotech
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas top stories
wisconsin blog main
wisconsin top stories
cancer
drugs
sanofi
texas blog main
bristol-myers squibb
celgene
crispr
eli lilly
fda
genentech
gilead sciences
intellia therapeutics
intercept pharmaceuticals
What
known
7
×
new
disease
drug
medicine
approved
bio
cancer
cells
crispr
fatty
led
liver
nash
roundup
adapt
biopharma
cancer’s
cas
cellular
changes
cholesterol
companies
congress
congressional
data
defect
digital
drive
drugs
edited
editing
epidemic
executives
expensive
faces
fda
fears
feud
financial
Language
unset
Current search:
known
×
" national blog main "
×
" san francisco top stories "
×
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
6 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells